Both Pfizer and Modena have applied for emergency authorization in the U.S. and Europe to approve their neo-crown vaccines. Both the European Union and the United States have indicated that they could approve and authorize the vaccine as early as the end of this year.
A spokesman for the European Commission said Tuesday that the European Medicines Agency will meet on Dec. 29 to decide whether to approve the new coronavirus vaccine developed by Pfizer in the U.S. and BioNTech in Germany.
The agency will decide as early as Jan. 12 whether to approve a new coronavirus vaccine developed by another U.S. company, Modena, the spokesman added. He said the review of the vaccine has already begun.
European Commission spokesman Stefan de Kesmek said, “This is now a decision that needs to be taken urgently, and if the Medicines Agency gives a positive analysis after a detailed analysis of the effectiveness and safety of the vaccine, then the European Commission will do everything it can to make a quick decision on authorization. Generally, we take into account that we need to consult the member states, but the Commission takes a decision as very quickly as possible, taking into account the urgency of launching a vaccine deployment.”
BioNTech, a German biotech company, said it is ready to ship the stockpiled vaccines once the European Medicines Agency or the U.S. Food and Drug Administration approves them.
Top EU officials said that about 2 billion doses of Neocon vaccine have been secured for 27 member states, with the first batch to be delivered by the end of the year.
On the other hand, U.S. Health and Human Services Secretary Henry Azar said the neo-crown vaccine developed by Pfizer could be approved as soon as Dec. 10 at a meeting to discuss emergency authorization, while Modena’s vaccine could be approved the week after that.
Recent Comments